An interventional study of group N used traditional nasal cannula for oxygen inhalation and Group HFNC used nasal high-flow oxygen inhalation. in COPD, sponsored by The First Affiliated Hospital of Guangzhou Medical University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by The First Affiliated Hospital of Guangzhou Medical University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Pulmonary Disease, Chronic Obstructive by The First Affiliated Hospital of Guangzhou Medical University — 4 open to participants now, 4 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · The First Affiliated Hospital of Guangzhou Medical University.
Among the 19 studies in Pulmonary Disease, Chronic Obstructive by The First Affiliated Hospital of Guangzhou Medical University, this one has the largest planned enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2026, is one of 13 with no phase, and was the 19th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →4 of the 19 studies in Pulmonary Disease, Chronic Obstructive by The First Affiliated Hospital of Guangzhou Medical University are open now, in 1 country. Recruiting first, the newest first:
The First Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 18+
The First Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 18+
The First Affiliated Hospital of Guangzhou Medical University
Ages 3+ · Healthy volunteers
By country, each count listing its studies:
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 25 across the 16 interventional studies, 100 across the 3 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
The First Affiliated Hospital of Guangzhou Medical University is the lead sponsor of 167 studies on the registry; 69 are open to participants now.
2 of the studies in Pulmonary Disease, Chronic Obstructive by The First Affiliated Hospital of Guangzhou Medical University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07631507The First Affiliated Hospital of Guangzhou Medical UniversityA Study to Evaluate the Diagnostic Performance of Portable Oscillometry Across Chronic Respiratory Diseases | 2027-07-30 |
| NCT07790822The First Affiliated Hospital of Guangzhou Medical UniversityCross-Regional Unmanned Aircraft Transport of Donor Lungs | 2027-09-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 19 studies in Pulmonary Disease, Chronic Obstructive by The First Affiliated Hospital of Guangzhou Medical University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Bronchoscopy diagnosis and treatment is highly irritating, and the effect of local topical anesthesia is poor; the airway is shared; and COPD patients have low oxygen reserves due to impaired lung function. At present, clinical anesthesia generally uses nasal cannula for oxygen inhalation. If the anesthesia is too shallow, it may cause airway spasm, and if the anesthesia is too deep, it will inhibit breathing and lead to hypoxia. Hypoxemia has been reported in 66% of COPD patients undergoing sedation for bronchoscopy. Therefore, solving hypoxia is the biggest problem in anesthesia for bronchoscopy diagnosis and treatment.
Bronchoscopy diagnosis and treatment is highly irritating, and local topical anesthesia has poor effect; deep sedation or intravenous anesthesia based on topical anesthesia is currently recommended; COPD patients have impaired lung function, and bronchoscopy diagnosis and treatment is accompanied by significant peri-anesthetic risks of hypoxemia. COPD patients are prone to hypoxemia due to the shared airway and sedative and analgesic drugs used to suppress breathing during bronchoscopy diagnosis and treatment. Therefore, solving hypoxia is the biggest problem for COPD patients during anesthesia during bronchoscopy. In recent years, studies have found that high-flow nasal oxygen therapy (HFNC) can significantly reduce the incidence of hypoxemia during anesthesia during bronchoscopy. However, very few studies have performed HFNC on patients with COPD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Group N used traditional nasal cannula to inhale oxygen during anesthesia.
Other: group N used traditional nasal cannula for oxygen inhalation
During anesthesia, the HFNC group used nasal high-flow oxygen inhalation
Other: Group HFNC used nasal high-flow oxygen inhalation.
1000 COPD patients who underwent bronchoscopy were randomly divided into 2 groups in a 1:1 ratio.Nasal high-flow oxygen therapy group(group N) and nasal cannula oxygen inhalation group(group HFNC).The N group used traditional nasal cannula for oxygen inhalation, and the HFNC group used nasal high-flow oxygen inhalation.
1000 COPD patients who underwent bronchoscopy were randomly divided into 2 groups in a 1:1 ratio.Nasal high-flow oxygen therapy group(group N) and nasal cannula oxygen inhalation group(group HFNC).The N group used traditional nasal cannula for oxygen inhalation, and the HFNC group used nasal high-flow oxygen inhalation.
pulse oximetry
Blood oxygen saturation during anesthesia, record the duration and number of times below 90%
Time frame: The entire anesthesia period during bronchoscopy
No study locations are listed for this record.
Plan to share: Yes — Upon completion of the study, de-identified individual participant data (IPD) and relevant supporting documents (e.g., study protocol, statistical analysis plan) will be shared upon reasonable request with researchers who provide a methodologically sound research proposal. Data will be made available starting 6 months after publication of the primary results and will remain available for 5 years. Requests must be submitted via [designated email or website], and a data use agreement must be signed.
Time frame: Beginning 6 months and ending 5 years following publication of primary results.
Access criteria: Researchers who provide a methodologically sound proposal. Proposals should be directed to [your email]. To gain access, data requestors will need to sign a data access agreement.
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Dec 2028, 27 months later.
Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 27 months is above that.
Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
The First Affiliated Hospital of Guangzhou Medical University →